CRISPR Therapeutics (NASDAQ: CRSP)
CRISPR Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
These rising drugmakers have serious arguments in their favor.
Is It Too Late to Buy CRISPR Therapeutics Stock?
The biotech has been making a lot of noise since late last year.
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
The biotech company keeps moving closer to bringing its promising first gene therapy to market.
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
This company's fortunes are likely to improve, and soon.
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
These exciting players could deliver explosive growth over time.
If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today
It would have been a great move.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.